SynthesisFrontiers in pharmacology2026
The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and invasive malignancies, with limited response to the currently available systemic therapy options. Having a 5-year survival of 12%, there is a serious need for novel therapeutic options, including drug repurposing for the treatment of PDAC. In recent years, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitors, also known as statins, have been identified as potential candidates for PDAC therapy repurposing. Methods: We have performed a scoping literature review to summarize the extent of knowledge on statins' effects on PDAC, both in clinical studies and preclinical models, and to explain the mechanisms underlying statins' antiproliferative effect on PDAC. We have followed the PRISMA Extension for Scoping Reviews (PRISMA-ScR) guidelines. We have searched PubMed and Web of Science for original articles published between January 2021 and January 2026. Results: Our review systematically linked the clinical outcomes, molecular mechanism, and tumor microenvironment in PDAC-statin research. Clinical studies of the correlation between statin treatment and PDAC incidence yielded mixed results. Among the mechanisms we have summarized are disruption of the plasma membrane lipid rafts, reduction of protein prenylation, increase of the tumor immunogenicity, reduction of signaling, both RAS-mediated and by alternative pathways, and disruption of mitochondrial respiration. Statins also showed synergistic effects with chemotherapeutic agents including gemcitabine, 5-fluorouracil, and oxaliplatin in preclinical models. Discussion: Despite promising preclinical data, the clinical evidence remains limited to observational studies and a single phase 2 trial. Randomized controlled trials with biomarker-driven patient selection are needed to establish the role of statins as adjuvant therapy in PDAC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.